-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Talazopanib (TALA) inhibits cytotoxic effects by inhibiting poly ADP-ribose polymerase (PARP) proteins 1 and 2 and "trapping" PARP on D.
Talazopanib (TALA) Talazopanib (TALA) Temozolomide (TMZ) Temozolomide ( TMZ) Second-Line Therapy for ES-SCLC
Methods: This study is an open-label, single-arm, phase 2 study of the safety and efficacy of TALA plus TMZ in ES-SCLC patients refractory/relapsed to first-line platinum-based regime.
TALA plus TMZ treatment
The primary outcome measure was objective response rate (ORR) based on RECIST 1 criteria, 15% ORR for previous second-line topotecan as control, and 8 or more confirmed responses in 28 evaluable subjects (29% ORR) were achiev.
Objective Response Rate (ORR)
RESULTS: A total of 31 subjects were included, 3 of whom could not be assessed due to ineligibility or premature withdrawal of consent prior to the first disease assessme.
Conclusion: The study exceeded its target response rat.
Benefits of low-dose TMZ inhibition of PARP beyond its target response rate
Original source:
Jonathan.
https://meetin.
leave a message here